Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT07673679

GliomaAI-Astro4: MRI-Based Detection of IDH Mutant Astrocytoma Grade 4

Conditions: Glioma, Glioma (Diagnosis), Astrocytoma, Astrocytoma, Grade IV, Astrocytoma, IDH-Mutant, Grade 4

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 1372
Sponsor: Deep Learning Institute of Radiological Sciences

Location: Deep Learning Institute of Radiological Sciences Mumbai

Summary

The goal of this observational study is to learn whether an artificial intelligence system called GliomaAI-Astro4 can help detect a specific molecular type of brain tumour called IDH mutant Astrocytoma Grade 4 using routine MRI scans. The study uses previously collected and fully anonymised MRI data from 1,372 patients from 13 institutions in the Cancer Imaging Archive (TCIA). The main questions it aims to answer are: * How accurately can GliomaAI-Astro4 identify IDH mutant Astrocytoma Grade 4 from MRI scans? * How well does the system perform across data from different hospitals and patient groups? Researchers will use existing MRI scans and clinical information to train and test the AI system. No new scans, treatments, or hospital visits are required for participants, and all data used is fully anonymised and obtained from an existing research database. Participants will not be asked to do anything, as this study only uses previously collected imaging data.

Eligibility Criteria

Inclusion Criteria: * Adult (\>=18 years of age) * Having pre op MRI scan * Having biopsy / surgery * Having post biopsy/ surgery histology diagnosis and genetic analysis. Exclusion Criteria: * MRI scan significantly degraded by motion or other artefact * Incomplete genetic analysis * Prior treatment (e.g., radiotherapy or chemotherapy) before baseline MRI

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07673679). StuddyBuddy aggregates publicly available trial information.